跳至主要内容
临床试验/ISRCTN26252543
ISRCTN26252543已完成未知

Effect of low glucose degradation product peritoneal dialysis solution Gambrosol-Trio on residual renal function in patients receiving peritoneal dialysis - a randomized controlled trial

Institute of Kidney Lifescience Technologies (Canada)0 个研究点目标入组 98 人开始时间: 2006年2月2日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
98

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Age 18 years or above
  • 2. Able to give consent
  • 3. Patient with Peritoneal Dialysis (PD) catheter inserted

排除标准

  • 1. Age less than 18
  • 2. Previous hemodialysis
  • 3. Those unlikely to continue peritoneal dialysis for more than six months due to severe comorbid conditions, planned living renal transplantation, or planned transfer to another facility
  • 4. Patients with previous renal transplant
  • 5. Patients starting incremental peritoneal dialysis
  • 6. 24-hour urine volume of less than 100 ml and/or creatinine clearance of less than 1 ml/min
  • 7. Patients with psychiatric diagnoses that might impinge on compliance

研究者

发起方
Institute of Kidney Lifescience Technologies (Canada)

相似试验